Navigation Links
Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Date:5/28/2008

ProLindac Demonstrates Sustained and Significant Reductions in Cancer

Market CA-125

DALLAS, May 28 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that the company gave an invited oral presentation on its lead anticancer compound, ProLindac(TM) at the International Symposium on Polymer Therapeutics: Laboratory to Clinical Practice, taking place from May 26-28 in Valencia, Spain. The presentation was entitled "Promising Safety and Efficacy Results from an Ongoing Clinical Study of ProLindac in Recurrent Ovarian Cancer." ProLindac is Access' novel DACH platinum-polymer prodrug, which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials.

The invited presentation was given by Professor Esteban Cvitkovic, M.D., Access Pharmaceuticals' Senior Director, Clinical Oncology R&D. Professor Cvitkovic presented data from the ongoing Phase 2 monotherapy clinical study of ProLindac in patients with recurrent ovarian cancer. In two dosing regimens, ProLindac was given once every two weeks and once every three weeks. During the last and highest dose levels explored, sustained and significant reductions in the specific serum market Ca-125 were seen over multiple dosings in several patients. ProLindac was well-tolerated with minimal side-effects.

"We continue to be impressed by clinical results that indicate a significant DACH platinum drug effect with a very benign side effect profile," stated Jeffrey B. Davis, Access' President & CEO. "The sustained efficacy and minimal toxicity seen over multiple dosings provides further evidence that ProLindac has the potential to become a very important anticancer agent in the future. We are finalizing our plans for Phase 2 combination trials where we intend to look at multiple solid tumor types with ProLindac in combination with other cancer agents, like taxol and gemcitabine."

ProLindac is currently in a Phase 2 dose-escalating monotherapy trial in recurrent ovarian cancer. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin(TM) or oxaliplatin.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; and Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Report on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
2. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
3. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
4. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
5. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
6. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
7. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
8. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
9. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
10. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
11. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to help doctors ... a global scale. Medical professionals from Europe , ... the US have already signed up for the app, which combines ... environment. Education  "Imagine a doctor for Medicines ... at Harvard to treat a bomb victim via live streaming - ...
(Date:5/23/2016)... -- Global Paclitaxel Market 2016 Industry Research ... and the Paclitaxel analysis in this study is supported ... its players. This is the latest Paclitaxel ... current state of the industry while providing a basic ... industry chain structure. The Paclitaxel market analysis is provided ...
(Date:5/23/2016)... NEW YORK , May 23, 2016 /PRNewswire/ ... Mass Spectrometry Market Size, Share, Development, Growth and ... Platform (Hybrid, Single and Other), by Application (Drug ... Others), by End Users (Pharmaceuticals, Life Science and ... Published by P&S Market Research, the global ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... Today Omega Institute, a ... 11 innovative workshops and training opportunities in the growing field of ... of individuals who are dealing with specific health issues—including injuries, illnesses, and temporary or ...
(Date:5/25/2016)... ... 2016 , ... Cheryl Bowker of Bowker Insurance Group has been presented with ... Legacy Award. McKenna ran one of Allstate’s most successful agencies for 48 years, but ... knew him. The award named for him is not given every year, but only ...
(Date:5/25/2016)... FL (PRWEB) , ... May 25, 2016 , ... The ... dive into the unique integrative medical wellness offerings of Europe, a continent that pioneered ... Tyrol, Austria will hear from numerous pioneers in medical wellness, including Henri Chenot, Founder ...
(Date:5/25/2016)... FL (PRWEB) , ... May 25, 2016 , ... ... Cross Benefit Clearinghouse supporting the real time adjudication of medical service claims by ... providers using their current medical claims management software. The TransactRx Cross Benefit Clearinghouse ...
(Date:5/25/2016)... ... May 25, 2016 , ... Conrad Siegel Actuaries, delivering ... and Prescription Drug survey , an employee benefits survey measuring how ... in December 2015, indicates that employers are turning to consumer directed health care ...
Breaking Medicine News(10 mins):